IPO registrations (S-1, F-1) · Registrants
ACCENTIA BIOPHARMACEUTICALS INC
- SEC CIK
- 1310094 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2005-02-11, last 2012-06-27; 6 initial registrations, 14 amendments
- Outcome
- Final prospectus filed 2005-10-28; declared effective 2006-06-22; withdrawal requested 2013-02-22
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- FL
- Business address
- 324 SOUTH HYDE PARK AVE, SUITE 350, Tampa, FL 33606
- EDGAR entity type
- operating
- Insiders and CEO pay
- ACCENTIA BIOPHARMACEUTICALS INC on the corporate pages
Offering terms
- Final price
- $8.00 per share (424B4 filed 2005-10-28, an initial public offering)
- Shares sold
- 2,400,000
- Gross proceeds
- $19,200,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ABPI
- Lead underwriters
- Jefferies; Stifel
- Syndicate
- Ferris, Baker Watts; GunnAllen Financial, Inc
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: ACCENTIA BIOPHARMACEUTICALS, INC. Fuzzy (name and state)
- Form D issuer: ACCENTIA BIOPHARMACEUTICALS INC EXACT (CIK (EXACT))
- SEC filer: ACCENTIA BIOPHARMACEUTICALS INC EXACT (CIK (EXACT))
- Person page: Francis E O'Donnell Jr Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: John P Dubinsky Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 31
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2005-02-11 | S-1 | S-1 (registration) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-027148 ↗ |
| 2005-04-06 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-071324 ↗ |
| 2005-05-16 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-108508 ↗ |
| 2005-06-13 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-123911 ↗ |
| 2005-06-27 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-131775 ↗ |
| 2005-06-30 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-135655 ↗ |
| 2005-07-11 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-139820 ↗ |
| 2005-09-02 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-179905 ↗ |
| 2005-10-03 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-195204 ↗ |
| 2005-10-19 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-203800 ↗ |
| 2005-10-19 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-203896 ↗ |
| 2005-10-27 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-209621 ↗ |
| 2005-10-28 | 424B4 | 424B4 (final prospectus) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-05-210460 ↗ |
| 2006-03-06 | S-1 | S-1 (registration) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-06-046273 ↗ |
| 2006-06-14 | S-1 | S-1 (registration) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-06-129875 ↗ |
| 2006-06-14 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-06-129884 ↗ |
| 2006-06-22 | EFFECT | EFFECT (declared effective) | ACCENTIA BIOPHARMACEUTICALS INC | 9999999995-06-000457 ↗ |
| 2006-06-23 | EFFECT | EFFECT (declared effective) | ACCENTIA BIOPHARMACEUTICALS INC | 9999999995-06-000465 ↗ |
| 2006-11-17 | EFFECT | EFFECT (declared effective) | ACCENTIA BIOPHARMACEUTICALS INC | 9999999995-06-002394 ↗ |
| 2007-07-17 | EFFECT | EFFECT (declared effective) | ACCENTIA BIOPHARMACEUTICALS INC | 9999999995-07-002830 ↗ |
| 2008-04-17 | EFFECT | EFFECT (declared effective) | ACCENTIA BIOPHARMACEUTICALS INC | 9999999995-08-001101 ↗ |
| 2008-09-24 | EFFECT | EFFECT (declared effective) | ACCENTIA BIOPHARMACEUTICALS INC | 9999999995-08-002930 ↗ |
| 2008-09-25 | EFFECT | EFFECT (declared effective) | ACCENTIA BIOPHARMACEUTICALS INC | 9999999995-08-002952 ↗ |
| 2011-02-18 | S-1 | S-1 (registration) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-11-040329 ↗ |
| 2012-02-03 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-12-038795 ↗ |
| 2012-03-15 | S-1 | S-1 (registration) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-12-117583 ↗ |
| 2012-03-15 | S-1/A | S-1/A (amendment) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-12-117594 ↗ |
| 2012-04-02 | EFFECT | EFFECT (declared effective) | ACCENTIA BIOPHARMACEUTICALS INC | 9999999995-12-000916 ↗ |
| 2012-06-27 | S-1 | S-1 (registration) | ACCENTIA BIOPHARMACEUTICALS INC | 0001193125-12-285645 ↗ |
| 2012-07-10 | EFFECT | EFFECT (declared effective) | ACCENTIA BIOPHARMACEUTICALS INC | 9999999995-12-002125 ↗ |
| 2013-02-22 | RW | RW (withdrawal request) | ACCENTIA BIOPHARMACEUTICALS INC | 0001214659-13-000988 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2005-10-27 | S-1/A | registration statement | $2.11 | - | - | 0 | primary document; price line | document ↗ | ||
| 2005-10-28 | 424B4 | final prospectus | $8.00 | 2,400,000 | $19,200,000 | Nasdaq ABPI | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| MOAB INVESTMENT LP | TenPercentOwner | 4 | 2006–2007 | ||
| RYLL DENNIS L | Director | 4 | 2006–2007 | ||
| RYLL TIMOTHY D | TenPercentOwner | 5 | 2006–2007 | ||
| ODONNELL FRANCIS E JR | Director; Director,Officer; Director,Officer,TenPercentOwner | CHAIRMAN & CEO; Chief Executive Officer; Executive Chairman; EXECUTIVE CHAIRMAN | 21 | 2006–2013 | person page Fuzzy |
| DUBINSKY JOHN P | Director | 3 | 2006–2008 | person page Fuzzy | |
| HOPKINS CAPITAL GROUP LLC | TenPercentOwner | 1 | 2006 | ||
| STOGEL STEVEN J | Director | 3 | 2006–2007 | ||
| KING EDMUND | Director | 5 | 2006–2012 | ||
| THOMASON TODD D | Director | 2 | 2006 | ||
| DUFFEY SAMUEL S | Officer | CEO/PRESIDENT/GENERAL COUNSEL; GENERAL COUNSEL; PRESIDENT AND GENERAL COUNSEL | 6 | 2007–2012 | |
| Pearce Alan M | Director,Officer; Officer | Chief Financial Officer | 10 | 2007–2011 | |
| Poole William | Director | 5 | 2007–2012 | ||
| ARIKIAN STEVEN | Director,Officer | Chairman/CEO; See General Remarks | 2 | 2008 | |
| SCHUBERT DAVID M | Director | 4 | 2008–2012 | ||
| CHAPMAN CHRISTOPHER C | Director | 4 | 2008–2012 | ||
| Calder Douglas W | Officer | VP Strategic Plan/Cap Markets | 3 | 2011–2012 | |
| Hasara Garrison J. | Officer | Acting Chief Financial Officer | 3 | 2011–2012 | |
| Santos Carlos | Officer | Chief Science Officer; Sr. VP of Prod Dev/Reg Affairs | 3 | 2011–2012 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2012-02-08 | ACCENTIA BIOPHARMACEUTICALS INC | Biotechnology | $5,000,000 | $400,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | ACCENTIA BIOPHARMACEUTICALS, INC. | FL | State business registries | name and state |
| Plan sponsor | ACCENTIA BIOPHARMACEUTICALS, INC. | FL | Form 5500 (employee benefit plans) | name and state |
| Form D issuer | ACCENTIA BIOPHARMACEUTICALS INC | FL | Form D private offerings | CIK (EXACT) |
| IPO registrant | BIOVEST INTERNATIONAL INC | FL | IPO registrations (S-1, F-1) | same street address and ZIP code, 324 S HYDE PARK AVE STE 350 33606 (FUZZY: a shared address, not proof of a shared organization) |
| Patent assignee | Accentia Biopharmaceuticals, Inc. | FL | Patents (USPTO) | name and state |
| SEC filer | ACCENTIA BIOPHARMACEUTICALS INC | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Accentia Biopharmaceuticals, Inc. | FL | Trademarks (USPTO) | name and state |
| Person page | Francis E O'Donnell Jr | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | John P Dubinsky | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, FL first:
- SANO CORP FL
- CTT PHARMACEUTICAL HOLDINGS, INC. FL
- Inhibitor Therapeutics, Inc. FL
- GENEREX BIOTECHNOLOGY CORP FL
- BIOMOLECULAR LIFE HOLDINGS, INC. FL
- Alaunos Therapeutics, Inc. FL
- ORAGENICS INC FL
- Polomar Health Services, Inc. FL
- NOMAD POWER SOLUTIONS, INC. FL
- CATALYST PHARMACEUTICALS, INC. FL
In other datasets, the same topic (Health) in FL:
- Nonprofit: 414 WELLWOMEN INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health